Urinary incontinence and pelvic organ prolapse in women: management Guideline Committee meeting 6

Date: 17/10/2017

Location: RCOG, London

Minutes: CONFIRMED



Committee members present:	
Fergus Macbeth (Chair)	(Present for notes 1-7)
Rohna Kearney (Topic advisor)	(Present for notes 1-7)
Karen Ward (Topic advisor)	(Present for notes 1-7)
Suzanne Biers	(Present for notes 1-7)
Jacqueline Emkes	(Present for notes 1-7)
Polly Harris	(Present for notes 1-7)
Sarah Love-Jones	(Present for notes 1-6)
Vikky Morris	(Present for notes 1-7)
Carmel Ramage	(Present for notes 1-7)
Lucy Ryan	(Present for notes 1-7)
James Stephenson	(Present for notes 1-6)
Kate Welford	(Present for notes 1-7)

In attendance:		
Andrew Harding	NICE Guideline Commissioning Manager	(Present for notes 1-7)
Judith McBride	NICE Senior Medical Editor	(Present for notes 1-7)
Lisa Boardman	NGA Guideline Lead	(Present for notes 1-7)
Melanie Davies	NGA Clinical Advisor	(Present for notes 6-7)
Elise Hasler	NGA Information Scientist	(Present for notes 1-2, 4-5, 7)
Eleanor Howat	NGA Project Manager	(Present for notes 1-7)
Laura Kuznetsov	NGA Systematic Reviewer	(Present for notes 1-7)
Charlotte Mahoney	NGA Clinical Fellow	(Present for notes 1-7)
Jose Marcano- Belisario	NGA Senior Systematic Reviewer	(Present for notes 1-7)

Observers:		
Maroulla Whiteley	NICE Business Analyst	(Present for notes 1-7)

Apologies:

Catherine Heffernan	Committee Member	
Doreen McClurg	Committee Member	
Carol Paton	Co-opted Committee Member	
Julian Spinks	Committee Member	
Patrice Carter	NGA Systematic Reviewer	
Eric Slade	NGA Health Economist	

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the sixth meeting on urinary incontinence and pelvic organ prolapse in women: management.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: reviewing the evidence and drafting recommendations, and discussing and amending review question protocols.

The Guideline Committee were informed that the colorectal consultant Co-opted Committee Member for this guideline had resigned. Recruitment for a replacement member on the committee was underway.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was urinary incontinence and pelvic organ prolapse in women: management.

The Chair asked everyone to verbally declare any interests that have arisen since appointment or that were specific to the topics being considered at this meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Kate Welford	Urogynaecology Clinical Nurse Specialist, UCLH NHS Foundation Trust	17.10.2017 Taken to dinner by Genisis Manufacturer of Urodynamic	Personal, financial, non-specific	Declare and continue

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations

The Chair introduced Laura Kuznetsov, NGA Systematic Reviewer, who gave a presentation on EVIDENCE REVIEW: 8.2 What is the effectiveness of topical oestrogen for managing pelvic organ prolapse with vaginal atrophy?

The Chair introduced Jose Marcano-Belisario, NGA Senior Systematic Reviewer, who gave a presentation on PROTOCOL: 8.5 What is the role of surgery to prevent postoperative urinary incontinence in women having surgery for pelvic organ prolapse, including the sequence of interventions?

The Chair introduced Jose Marcano-Belisario, NGA Senior Systematic Reviewer, who gave a presentation on PROTOCOL: 11.2 What are the most effective management options for sexual dysfunction after mesh surgery?

The Chair introduced Charlotte Mahoney, NGA Clinical Fellow, who gave a presentation on EVIDENCE REVIEW: 10.1 What is the most effective strategy for assessing complications (for example, vaginal complications, sexual dysfunction, pain, urinary symptoms and bowel symptoms) after mesh surgery?

The Chair introduced Jose Marcano-Belisario, NGA Senior Systematic Reviewer, who gave a presentation on PROTOCOL: 9.1 What is the most effective surgical management for women with both stress urinary incontinence and pelvic organ prolapse, including the sequence of interventions?

The speakers took questions from the group. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked the speakers for their presentations.

5. Questions and discussion

The Committee discussed the presentations and were given the opportunity to ask questions, draft recommendations and rationale and impact sections following evidence reviews, and agree amendments to the review protocols.

6. Other issues

The Committee considered the following equalities issues:

 The Committee considered the most effective ways to administer vaginal oestrogen to women with cognitive or physical disabilities, and agreed that this should be outlined in the guideline.

The Committee considered the following implementation issues:

• No specific issues were raised at this meeting.

7. AOB

The Guideline Lead agreed to let the committee know about the following:

- Reminder of membership of topic groups
- Provide examples of patient decision aids

Date of next meeting: 27 & 28 November 2017

Location of next meeting: RCOG, London